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ABSTRACT 
 
 
Rotational Behavior during the Pole Test:  
A Novel Behavioral Assay in a Mouse Model of Parkinson’s Disease 
 
 
Mariah Barry 
Department of Biomedical Sciences 
Texas A&M University 
 
 
Research Advisor: Dr. Rahul Srinivasan 
Department of Neuroscience and Experimental Therapeutics 
Texas A&M University 
 
 
Parkinson’s disease (PD) is a debilitating disorder that is likely to reach pandemic 
proportions by the year 2040, and there is no cure. Current treatments are symptomatic in 
nature and often have deleterious side effects, such as L-dopa-induced dyskinesia. 
Neuroprotective drugs, however, target the cause of PD, which is neuronal death; these drugs 
may prevent motor deficits from progressing in patients with PD. The development of 
neuroprotective drugs, however, requires a reliable and clinically translatable animal model 
for PD. The classic preclinical model for testing drugs for PD is a rodent model based on 
intracranial injections of 6-hydroxydopamine (6-OHDA), a neurotoxin that results in the loss 
of dopaminergic neurons. Injection of 6-OHDA into the dorsolateral striatum of rodents 
results in retrograde degeneration of dopaminergic axons, resulting in the loss of 
dopaminergic neuronal cell bodies within the substantia nigra pars compacta (SNc), which is 
the brain region lost in PD. Unilateral lesioning with 6-OHDA damages only one side of the 
SNc, and the extent of damage can be quantified with drug-induced rotational assays. These 
behavioral assays, while effective, require administration of additional drugs to induce 
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rotations. The use of drugs, specifically apomorphine or amphetamine, to induce rotations in 
6-OHDA injected rodents is problematic because of potential drug-drug interactions, 
especially in the setting of drug discovery. To address this issue, I developed a new 
behavioral assay that induces rotational behavior during a motor task without the need for 
additional drugs. I utilized either sham-operated or ovariectomized female mice that were 
injected with 6-OHDA into the dorsolateral striatum. These mice were subjected to a 
specialized task in which the mice were required to turn and descend down a 2-foot pole. 
Three trials per mouse were conducted at 5 time points, which included 2 time points prior to 
6-OHDA injection and 3 time points following 6-OHDA injection; each time point was at 
least one week apart. I quantified several parameters utilizing this assay format, including the 
time to turn, time to descend, average score of descent, direction of rotations, and number of 
rotations. Results showed that 6-OHDA significantly increased the number of rotations in 
both ovariectomized and sham-operated female mice without the use of any additional drug. 
My data suggest that spontaneous rotations whilst performing a specialized task such as 
descent down a 2-foot pole are a useful measure for the discovery of preclinical 
neuroprotective drugs to treat PD.  
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NOMENCLATURE 
 
 
PD  Parkinson’s disease 
 
SNc  Substantia nigra pars compacta 
 
6-OHDA 6-hydroxydopamine 
 
DAT  Dopamine transporter 
 
PBS  Phosphate-buffered saline 
 
OCT  Optimum Cutting Temperature 
 
NGS  Normal goat serum 
 
TH  Tyrosine hydroxylase  
 
VTA  Ventral tegmental area 
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CHAPTER I 
INTRODUCTION 
 
 
Parkinson’s Disease 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by both motor 
and non-motor symptoms. Motor symptoms include primary symptoms, such as impaired 
voluntary motor control, slow movement, tremors at rest, stiffness, frail posture, as well as 
secondary symptoms, such as shuffling gait, cramped handwriting, weakened gripping, difficulty 
speaking, and eventually immobility.1 Non-motor symptoms include depression, anxiety, 
irritability, difficulty with executive function, dementia, hallucinations, and more.2 While PD 
used to be considered a rare disorder, it will likely reach pandemic proportions in the next 20 
years; the number of global cases has doubled since 1990 to over 6 million cases, and the number 
is projected to climb to over 12 million cases by 2040.3 Given that the cost of caring for a patient 
with PD in the United States is approximately $22,800 annually, the national economic burden of 
PD is expected to increase substantially in the next few decades.4 Despite its discovery in 1817, 
PD is still largely untreatable.3  
Pathophysiology 
Symptoms for PD result from the gradual loss of dopaminergic neurons in the substantia 
nigra pars compacta (SNc), a brain region located within the midbrain that is crucially involved 
in motor function.5 The aggregation of alpha-synuclein proteins within the SNc, known as Lewy 
bodies, is also associated with PD; the neurotoxic buildup interrupts neuronal functioning.5 
While the exact biochemical mechanisms behind PD remain unknown, there are multiple 
suspected causes. Some genetic mutations have been tied to PD, including those in the PINK1 
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gene; mutations in PINK1 have been known to promote aggregation of alpha-synuclein.5 
Additionally, exposure to environmental toxins may also be linked to PD.5 However, none of 
these suspected causes alone account for most cases of PD; instead, multiple factors likely 
interact to collectively result in oxidative stress, neural inflammation, and eventual 
neurodegeneration.5,6 
Sex Differences 
 While being above the age of 65 is one of the most well-known risk factors for 
developing PD, there is a significant disparity between sexes as well.7,8 PD affects both men and 
women, but it is twice as prevalent in men.9 Male susceptibility to PD is likely enhanced due to 
biological differences in brain physiology and endocrinological function. The female 
nigrostriatal pathway has an increased endogenous concentration of dopamine, which translates 
to better performance in dopamine-related motor and cognitive functioning relative to men.10 PD 
is associated with reduced dopamine transmission within the nigrostriatal pathway; thus, 
naturally higher levels of dopamine in the female brain may be partially responsible for their 
reduced susceptibility to PD.8,10 Furthermore, sex hormones may also impact the progression of 
neurodegenerative diseases. Some research has suggested that estrogen is actually 
neuroprotective, and can reduce dopaminergic neuron loss, whereas testosterone has a 
detrimental effect.8 Understanding the mechanism by which estrogen exerts neuroprotection 
could allow for the development of neuroprotective drugs to treat PD in humans. 
Neuroprotective Drugs 
Current treatments do not focus on the underlying causes of PD, but rather target 
symptoms. Because many symptoms result from reduced dopamine levels within the striatum, 
dopamine agonists such as L-3,4-dihydroxyphenylalanine (L-dopa) are often administered to 
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patients.11 While drugs like L-dopa can be helpful initially, they are associated with harmful side 
effects; they also tend to lose effectiveness over time.11 
Alternatively, neuroprotective drugs have become a favored area of research regarding 
neurodegenerative diseases; these drugs are designed to slow down degeneration of neurons and 
provide protection against future damage.12 In patients with PD, neuroprotective drugs may 
specifically help to reduce cell death in striatal dopaminergic neurons. Currently, there are no 
neuroprotective drugs available as treatment for PD. Interestingly, nicotine and tobacco usage are 
inversely correlated with the development of this disease because of associated neuroprotective 
side effects.13 Due to the dangerous side effects and the likelihood of addiction, nicotine would 
cause more harm than benefit as a treatment for PD. Cytisine, which is a smoking-cessation drug 
with similar structural and functional properties as nicotine, lacks addictive properties and may 
be a viable neuroprotective treatment option for PD.14  
Models of Parkinson’s Disease 
In order to develop better neuroprotective treatments for PD, a biological model that 
replicates the disease in humans must be developed. The gold standard model for PD is the 6-
hydroxydopamine (6-OHDA) rat model, with 6-OHDA administered either unilaterally or 
bilaterally.6 6-OHDA is a neurotoxin that specifically causes cell death in dopaminergic neurons 
of the substantia nigra pars compacta (SNc), the same area of the brain affected in humans with 
PD.6 Using stereotaxic injection, the toxin can be administered to the rodent’s striatum, a section 
of the forebrain integral to the nigrostriatal pathway.15 In this pathway, dopaminergic neurons in 
the SNc project to the striatum, releasing dopamine upon firing. When the neurotransmitter is no 
longer needed in the synapse, it is cleared away using a dopamine transporter (DAT), which 
returns dopamine to the presynaptic neurons originating in the substantia nigra.15 Because 6-
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OHDA is similar in structure to dopamine, the DAT returns the toxin to the neurons, leading to 
neuron death in the substantia nigra, as seen in patients with PD.6 While the nigrostriatal 
pathway does not initiate movement, it is vital for regulating motor function; thus, when 
dopaminergic neurons die, affected individuals begin to experience dyskinesia.5  
While the 6-OHDA model of PD reproduces many aspects of the disease, it tends to 
cause neuronal death quickly rather than the realistic slow onset of symptoms, and it fails to 
cause the aggregation of proteins.16 Alpha-synuclein overexpression has recently become another 
model for PD. Alpha-synuclein is the primary constituent of Lewy bodies; injecting viral vectors 
carrying the alpha-synuclein gene into the substantia nigra can lead to the artificial agglutination 
of the protein in rodents.16 Overexpression of alpha-synuclein leads to gradual 
neurodegeneration, at a rate more comparable to that of PD in humans. However, 
neurodegeneration in the alpha-synuclein model is only moderate compared to that seen in the 6-
OHDA models, and motor dysfunction is less apparent as well.16  
Estrous Cycling and the Role of Estrogen 
 Ovariectomies can be performed on female mouse models of PD in order to better 
understand the effect of the absence of estrogen on the development of PD, as seen clinically in 
men or postmenopausal women. Ovariectomy, or excision of the ovaries, removes the primary 
source of estrogen in the female mouse; the success of ovariectomies can be determined through 
vaginal smearing and cytological analysis.17 The mouse estrous cycle, comparable to the human 
menstrual cycle, lasts approximately 4 days, and has 4 definitive stages: proestrus, estrus, 
metestrus, and diestrus.18 The stage is determined by the predominant cell types present in the 
female reproductive tract, which is in turn determined by varying levels of sex hormones.18 
During the proestrus stage, estrogen, luteinizing hormone, and follicle-stimulating hormone are 
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all at their peak concentration; nucleated epithelial cells predominate in vaginal smears at this 
stage.19 The subsequent stage is estrus. During estrus, prolactin reaches its peak concentration 
while all the other hormones drop to low levels; vaginal smears are characterized by showing 
predominantly cornified epithelial cells.19 The third stage, metestrus, is characterized by a slight 
increase in estrogen and progesterone; vaginal smears exhibit nucleated epithelial cells, cornified 
epithelial cells, and neutrophils.19 Finally, during diestrus, estrogen levels are at their lowest 
concentration whereas progesterone levels are at their highest concentration; neutrophils 
predominate in vaginal smears at this stage.19 
Behavioral Assays 
Behavioral assays are a quantitative method to ensure the validity of a given model. 
While no model has consistently demonstrated all of the motor and non-motor symptoms of PD 
in humans, various tests can be used to measure the range of symptoms that are present in 
models.20  
Tests such as the open field test and apomorphine-induced rotations test allow for 
observation of general activity, locomotion, as well as anxiety or stress levels. The apomorphine-
induced rotations test in particular highlights the damage done to the nigrostriatal pathway in 
rodents with unilateral lesioning.21 Intraperitoneal injections of apomorphine or amphetamine, a 
dopamine agonist and synergist, respectively, will cause heightened activity in the dopaminergic 
neurons of the nigrostriatal pathway. If one side of the brain has been lesioned with 6-OHDA, 
unbalanced dopamine release will occur, resulting in one-sided movement, or rotational 
behavior; a greater degree of damage on one side will result in an increased amount of rotation.22 
The open field test involves placing the mouse in an arena with a designated inner zone; the 
mouse is then monitored for its total distance traveled, average speed, and the amount of times it 
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enters into and remains in the inner zone.23 This test allows for measurement of both motor and 
non-motor characteristics, including locomotor ability and anxiety levels.23 
Tests such as the pole test, cylinder test, challenging beam test, and grip strength test 
allow for verification of motor symptoms in PD models. In the pole test, the mouse must turn 
down and descend a 2-ft pole; this test is used to measure motor coordination and bradykinesia in 
the mice.24 The cylinder test is one in which the mouse is placed in a glass cylinder and removed 
after rearing up to touch the sides of the cylinder 20 times. This test verifies whether the mouse 
exhibits asymmetry between the use of their limbs when touching the glass.24 During the 
challenging beam test, the mouse must traverse an increasingly narrow beam, which is covered 
with a raised mesh grid; motor coordination is measured in this test based on the mouse’s speed, 
head orientation, and the number of times a foot slips through the grid.24 Lastly, the grip strength 
test is used to determine the extent of muscle weakness in one limb compared to the other, which 
again reflects the extent of damage to the nigrostriatal pathway on one side of the brain.25 Given 
that the 6-OHDA model exhibits a clinically translatable amount of neurodegeneration, verified 
through measured motor and non-motor deficits, it can be utilized as a model for PD in humans. 
This provides the necessary foundation for therapeutic testing. 
Objectives 
My primary objective was to develop a mouse model of Parkinson’s disease using 
unilateral stereotaxic striatal injections of 6-OHDA, then perform ovariectomies on half of the 
mice to determine the effect of estrogen, or lack thereof. With these animal models, I then 
conducted various behavioral assays on the mice to determine a new method of quantifying PD-
related pathophysiology in mouse models. In my study, I developed a novel assay based on 
spontaneous rotational behavior that occurs as the mouse descends down a pole. This new assay 
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provides several advantages, as it provides simultaneous measurements of motor coordination 
and dopamine release without the need for injection of additional drugs.  
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CHAPTER II 
METHODS 
 
 
Experimental Timeline and Overview 
This project took place over the course of 6 weeks, using a cohort of 9 female mice. Out 
of these, 5 females were ovariectomized and 4 females received sham surgeries. Sham surgeries 
and ovariectomies took place on the third day of week 1. Additionally, all of the mice received 
intrastriatal injections of 6-OHDA on the fourth day of week 3. Behavioral training took place 
one day before behavioral testing throughout the project timeline. Behavioral testing occurred on 
the third day of week 1 prior to ovariectomies and sham surgeries, the third day of week 2, the 
third day each of week 4, 5, and 6; the last three days of behavior testing occurred after 
intrastriatal injections of 6-OHDA. Vaginal smears were collected every day throughout the 
experiment timeline, beginning on the first day of week 1. The mice were sacrificed after 
behavioral testing ended on the third day of week 6. Figure 1 depicts the timeline details for 
behavioral testing, ovariectomies, sham surgeries, and 6-OHDA injections. Behavior tests that 
were performed included the novel object recognition test, apomorphine rotations, cylinder test, 
ladder test, and pole test. For the purposes of this capstone project, the pole test will be the only 
behavioral protocol explained. 
 
 
Figure 1. Experiment Timeline 
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Chemicals and Materials 
Nine female CL57BL/6 mice were utilized in this experiment; they were maintained in 
the Medical Research and Education Building at the Texas A&M Health Science center in the 
vivarium. Mouse cages included a wire rack for holding food and a water dispenser bottle. Both 
ovariectomies and sham surgeries required isoflurane and 100% oxygen for anesthetization. 
Mice were weighed on a scale, and clippers were used to shave fur around the incision site. 
During surgery, iodine, 70% ethanol, a scalpel, cotton swabs, and eye lubricant were utilized. 
After surgery, mice were placed in their home cage on a heating pad, and given peanut butter and 
water.  
Vaginal smearing required 0.9% saline, 70% ethanol, and double-distilled water; the 
saline was purified through a filter prior to beginning. Three Falcon 50 mL tubes were utilized to 
hold the saline, ethanol, and waste during the smearing process. A one-mL eyedropper was used 
to inject saline and collect cells. Smear samples were collected using a 48-well cell plate. 
Samples were viewed on a 25x75 mm glass slide and stained with crystal violet stain. Glycerol 
was used to cover the smear, and a 24 x 60 mm coverslip was placed on top. An Olympus CK2 
light microscope was used to visualize vaginal smear cell morphology. 
For stereotaxic injection of 6-OHDA, mice were anesthetized with isoflurane 
administered through a Kent Scientific SomnoSuite Low Flow Anesthesia System. For surgery, 
clippers, a scalpel, rat-toothed forceps, scissors, and eye lubricant were also used. Lesions were 
made using a Kopf Instruments stereotaxic apparatus. 10 μg of 6-OHDA in 0.9% saline and 
0.2% ascorbic acid was administered via glass-pulled pipettes. 
The pole test utilized a pole comprised of a rod that was 2 feet long and 0.5 inches in 
diameter. A 3-inch x 3-inch piece of cardboard was screwed to the top of the rod. The base plate 
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was approximately 8 inches long, 4.5 inches wide, and ¾ of an inch tall. Wood shavings were 
used for bedding, and all were placed in the bottom half of a rat cage. Rescue animal cleaner was 
used to clean the pole and rat cage. A 4K Ultra-HD digital video camera was used to record 
behavior on test days, and video recordings were stored on a 32-gigabyte or 64-gigabyte SanDisk 
memory card. 
For transcardial perfusion, isoflurane inhalant was used to deeply anesthetize the mice. 
The perfusion took place in a fume hood; a scalpel, scissors, and 24-gauge injection needle were 
used. Gibco phosphate-buffered saline (PBS) and 10% formalin were injected. After perfusion, a 
spatula, VWR 15 mL tube, and 10% formalin, and 30% sucrose were used for brain tissue 
storage. 
Brain slices were obtained using a Microm HM 550 cryostat, a single-edge razor blade, 
and Fisher Healthcare optimum cutting temperature (OCT) embedding medium. Slices were 
stored in 1% sodium azide in a 24-well cell plate. 
The immunofluorescence staining process required a 24-well cell plate, Gibco PBS, a 
Thermo Scientific MaxQ 2506 Lab Shaker, small paintbrushes, normal goat serum (NGS), 
Sigma Triton X-100, and both primary and secondary antibodies. The primary antibody used was 
chicken anti-tyrosine hydroxylase, diluted 1:1500. The secondary antibody used was goat anti-
chicken 594, diluted 1:2000. Slices were mounted on a 25x75 mm glass slide using fluoromount 
and a 24 x 60 mm coverslip; the edges were sealed with nail polish. Slides were imaged using an 
Olympus confocal scanning laser microscope. 
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Ovariectomy and Sham Surgery Procedures 
Ovariectomy Procedure 
Five female mice underwent ovariectomies. The mice were weighed immediately prior to 
surgery. Mice were then anesthetized with isoflurane in an induction chamber; they were 
removed when breathing slowed down to one deep breath per second. Fur on the back was 
shaved with a clipper. During surgery, mice remained anesthetized using vaporized isoflurane 
mixed with 100% oxygen. Mice were placed in the prone position, and two 1-cm incisions were 
made parallel to each side of the lumbar vertebrae. A 1-cm incision was made just behind the 
peritoneum on the erector spinae muscle to reach the ovaries. On each side, uterine blood vessels 
distal to the ovaries were ligated. Then part of the uterine horns, the ovaries, the oviducts and the 
surrounding fat were all excised. The incision was then closed and the mouse returned to its 
home cage. Mice were given peanut butter and water daily in small Petri dishes following 
surgery. 
Sham Surgery Procedure 
Four female mice underwent sham surgeries. The same protocol in the Ovariectomy 
Procedure section above was followed, but uterine vessels, ovaries, oviducts, uterine horns, and 
surrounding fat remained intact for each mouse. Then the incision was reclosed, and the mouse 
was returned to its home cage. The mice were also supplemented with peanut butter and water. 
Vaginal Smear Protocol 
To determine the estrous cycle phases occurring in both the ovariectomized and sham-
operated mice, vaginal smears were collected daily during the experiment. Prior to collecting 
smears, a 0.9% filtered saline solution was prepared. Three 50 mL beakers were used, one filled 
with the filtered saline solution, one filled with ethanol, and one left empty for waste disposal. A 
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48-well cell plate was labeled with identification numbers for each mouse. To begin, the cage 
was opened with the wire rack left in place. The first mouse was removed from the cage and 
placed on the wire rack, then grasped by the scruff of the neck by the handler’s non-dominant 
hand to immobilize the arms and head of the mouse. If the mouse urinated, it was allowed to 
finish and then was cleaned with double-distilled water. An eyedropper with a rubber bulb was 
filled ¾ full with saline solution, then inserted into the vagina of the mouse. The contents of the 
eyedropper were released inside the vagina, then sucked back into the eyedropper. This was 
repeated 4-5 times until enough cells were contained in the saline solution. The eyedropper was 
removed and the mouse was placed back in the cage. The solution was then dispensed into the 
appropriate well for that mouse, and the eyedropper was cleaned using filtered saline, 70% 
ethanol, then filtered saline again. The procedure was repeated for all the female mice.  
To visualize cell morphology, a drop of saline containing cells obtained from each mouse 
was placed on a glass slide and dried at room temperature. The slide was completely covered 
with crystal violet stain for six minutes, then rinsed with double-distilled water. Excess water 
was removed, then approximately 15 μL of glycerol was placed on top of the smear and the 
smear was covered with a glass coverslip. The cells were viewed immediately under a light 
microscope, and pictures were taken at 10x and 20x magnification. 
Stereotaxic Injection of 6-OHDA 
Two weeks after ovariectomies and sham surgeries, all 9 mice were stereotaxically 
unilaterally injected with 6-OHDA. Mice were anesthetized with isoflurane in an induction 
chamber until they were breathing one deep breath per second. The fur on their head between 
their ears and nose was shaved with clippers, and they were placed on the stereotaxic apparatus. 
Mice were continuously anesthetized during surgery using isoflurane. Once immobilized, the 
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skin of the head was incised and reflected laterally from the midline. A craniotomy was 
performed 0.8 mm anteroposteriorly, 2.0 mm mediolaterally, and 2.4 mm dorsoventrally. The 
neurotoxin, which was 10 μg of 6-OHDA in 0.9% saline and 0.2% ascorbic acid, was injected 
unilaterally into the mouse striatum via glass-pulled pipette at a rate of 750 nL/min. After 
injection, the needle was carefully removed, and the head was sutured shut. After surgery, mice 
were placed back in their home cage on a warming pad and supplemented with peanut butter and 
water.  
Pole Test and Analysis  
For pole test, the mice received two days of training prior to the first day of behavioral 
testing, then one day of training prior to each subsequent test day. For both training and testing, 
the pole used was 2 feet long and 0.5 inches in diameter. There was a cardboard topper and a 
heavy base plate at the bottom. The pole was placed in a clean rat cage surrounded with bedding.  
Training Days 
The pole was tipped until almost horizontal, and the mouse was placed on the pole nose-
up toward the cardboard topper. When each mouse was placed on the pole, the tail was manually 
stabilized while the pole was returned to the vertical position. Following release, the mouse had 
to turn nose-down on the pole and then descend until all four limbs were on the base plate. In 
cases where the mouse failed to turn within 15 seconds, the mouse was manually turned by 
gently pulling the tail up toward the cardboard topper. This trial was repeated three times for 
each mouse. Following each training session, the mouse was returned to its home cage. In 
between littermates of the same cage, urine and fecal matter was removed from the pole and base 
plate with a clean cloth, while for mice from different cages, the pole was thoroughly wiped 
down with rescue animal cleaner. 
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Testing Days 
Prior to testing, the digital video camera was set up on the tripod so that the entire pole 
test apparatus was visible. Once recording had begun, a sign with the day number, date, cohort 
number, test, and mouse identification number was passed in front of the camera. With the pole 
held almost horizontally, the mouse was placed on the pole nose-up toward the cardboard topper. 
Their tail was manually stabilized until the pole was vertical again. When the pole reached the 
vertical position and the hand was removed from the pole, then a timer was started. If the mouse 
turned on its own and descended, then it was placed on the pole again for its second trial. If the 
mouse failed to turn after 60 seconds, only then would the mouse be guided to turn down by 
having its tail pulled up toward the top of the pole. Each mouse underwent three trials. Prior to 
recording the next mouse, a sign with updated information for that mouse was passed in front of 
the camera. Protocol for cleaning the pole between littermates of the same cage and mice of 
different cages was the same as training days. After all mice finished testing, the camera 
recording was stopped. 
Analysis 
The pole test videos were manually analyzed. For each trial, each mouse was analyzed 
according to its time to turn down while on the pole, the time it took to descend the pole, and the 
average score of descent. The start time for each trial began when the mouse was placed 
vertically in the starting position (nose-up), after the hand was removed from the pole. The time 
to turn was defined as the amount of time it took from start time for the mouse to turn 180° so it 
was facing nose-down, after bringing its hind limb around to reposition itself on the pole. See 
Figure 2. 
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Figure 2. Example of mouse turning 180° and bringing hind paw around. 
 
The time to descend was recorded as the time after turning until the time the mouse 
touched the base plate at the bottom of the pole with all four limbs. The score of descent was 
given based on a scale from 0 to 5, with 5 being the best. The scoring system was as follows: 0 = 
mouse stayed at top for 60+ seconds; 1 = mouse fell; 2 = mouse descended backwards; 3 = 
mouse descended sideways; 4 = mouse turned after descending halfway; 5 = mouse turned at top 
and descended. For each mouse, the data from all three trials were averaged. 
Due to observation of spontaneous rotations, particularly after unilateral lesioning with 6-
OHDA, the number of rotations for each trial was also retrospectively quantified. One rotation 
was defined as one 360° turn around the pole, measured only during the time it took for the 
mouse to descend. The number of rotations recorded was also averaged from the three trials for 
each mouse. 
Sampling and Statistics 
OriginLab software was utilized to perform two-way repeated measures ANOVA tests 
(surgical treatment*time) for significance testing in time to turn, time to descend, average score, 
and number of rotations for each group of females, ovariectomized or sham-operated. 
Significance testing was done for the weeks prior to 6-OHDA (week 1 and 2) and the weeks after 
6-OHDA (weeks 4, 5, and 6) for each of the four data sets.  
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Transcardial Perfusion and Brain Slicing 
Transcardial Perfusion 
After all testing was complete, mice were deeply anesthetized using isoflurane. Then they 
were placed in the supine position on a platform within a fume hood for transcardial perfusion. 
An incision was made perpendicular to the midline just below the ribcage. Another incision was 
made through the skin and ribs from the most lateral aspect of the ventral ribcage toward the 
clavicle. A second incision was made on the contralateral side through the ribcage so that the 
front-facing ribcage could be reflected cranially, exposing the entire thoracic cavity. With the 
heart visible, a needle containing PBS was inserted into the left ventricle, and approximately 1.5 
mL of PBS were injected to flush out the circulatory system. The vena cava was then transected 
to exsanguinate the mouse. Once PBS had been injected, a needle containing 1.5 mL of 10% 
formalin was inserted into the left ventricle, and its contents were released into the circulatory 
system. After 10 minutes of formalin profusion, the needle was removed and the mouse was 
decapitated. A sagittal incision was made through the skin on along the length of the skull and 
the skin was reflected laterally from the midline. The skull was transected between the eyes and 
down each side toward the dorsal aspect of the head. The top of the skull was then removed, 
exposing the brain. The brain was removed from the skull with a spatula and placed in a 15 mL 
tube filled with 10% formalin; the tube remained in a 4°C cooler overnight. The following day, 
the brain was transferred to a 30% sucrose solution and stored in a 4°C cooler until needed. 
Brain Slicing 
The brain was retrieved from its storage site in 30% sucrose and sliced using a cryostat 
machine set to -24°C. The olfactory bulbs and cerebellum were removed, and the brain was 
mounted rostral-side up on a chuck with OCT embedding medium. OCT medium was used to 
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cover the brain. When the brain and OCT medium were fully frozen, the chuck was mounted to 
the cryostat slicing machine. The slicer was set to cut at a thickness of 100 μm, and the first few 
slices were used to adjust the brain so it was properly positioned. Then, 100 μm brain slices were 
collected and placed in a 24-well cell plate. As the slicer approached the midbrain, 40 μm slices 
were collected and placed in the 24-well cell plate. After the brain slices were collected, the 
slices were put in 1% sodium azide and stored in a 4°C cooler until needed. 
Immunofluorescence Staining and Imaging 
Immunofluorescence Staining 
For each mouse, 2-4 midbrain slices were selected and transferred via a small paintbrush 
into a 24-well cell plate. The slices were washed twice with PBS for 5 minutes each on an 
agitator. Then slices were placed in a blocking and permeabilizing solution consisting of 10% 
NGS and 0.5% Triton X-100 in PBS. Slices remained in the blocking and permeabilizing 
solution for one hour, and then they were washed twice more in PBS for 5 minutes with 
agitation. The slices were incubated in the primary antibody solution, which had 1% NGS, 
0.05% Triton X-100, and a chicken anti-tyrosine hydroxylase antibody diluted 1:1500. The brain 
slices remained in the primary antibody solution overnight with agitation in a 4°C cooler. 
The following day, the slices were removed from the primary antibody solution and 
washed twice with PBS for 5 minutes each with agitation. The slices were then incubated in a 
secondary antibody solution for one hour; the solution consisted of 1% NGS, 0.05% Triton X-
100, and a goat anti-chicken 594 antibody diluted 1:2000. After secondary antibody incubation, 
the slices were washed twice with PBS for 5 minutes with agitation. The slices were transferred 
onto glass slides labeled with the date, mouse number, and antibody information. Once dry, the 
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slices were covered in fluoromount, and a coverslip was placed on top. The slides were left to 
fully dry, and then sealed with nail polish around the edges. 
Imaging 
Slides were imaged using confocal scanning laser microscopy. Images were taken at 10x 
magnification, and tyrosine hydroxylase (TH), a marker for dopaminergic neurons, was tagged 
and fluorescently highlighted in the images. Images of the substantia nigra pars compacta (SNc) 
and the adjacent ventral tegmental area (VTA), a part of the brain involved in reward, were taken 
on both the unlesioned side of the brain and the side lesioned with 6-OHDA. Four images were 
taken for each brain slice, and the images were spliced together to show a representation of 
dopaminergic neuron levels within the midbrain.  
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CHAPTER III 
RESULTS 
 
 
Vaginal Smears 
 Vaginal smears from both ovariectomized and sham-operated groups of females were 
observed under a microscope and compared based on the present cell morphologies. Analysis of 
vaginal smears from sham-operated females revealed that the cell morphology varied on a daily 
basis, corresponding with sequential phases of estrous cycling in the mice. Figure 3 shows 
vaginal smears from a female mouse who received a sham surgery and was still undergoing 
estrous cycling. Image A shows an abundance of nucleated epithelial cells, indicating proestrus. 
Image B shows an abundance of cornified epithelial cells, indicating estrus. Image C shows a 
combination of nucleated epithelial cells, cornified epithelial cells, and neutrophils, indicating 
metestrus. Image D shows an abundance of neutrophils, indicating diestrus. 
 
 
Figure 3. Images of vaginal smears from a sham-operated female over 4 consecutive days.  
 
Vaginal smears from ovariectomized females showed regularity in cell morphology from 
day to day, as seen in Figure 4. Images E, F, G, and H in Figure 4 all show an abundance of 
neutrophils, indicating that the mouse was in a prolonged stage of diestrus. Figures 3 and 4 show 
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a stark contrast in the cell morphologies presented in the ovariectomized females versus the 
sham-operated females over the length of one estrous cycle. 
 
 
Figure 4. Images of vaginal smears from an ovariectomized female over 4 consecutive days. 
 
 One of the mice continued cycling despite removal of the ovaries; all other 
ovariectomized females showed estrous cycle disruption. The behavioral data for this anomalous 
mouse were discounted. 
Midbrain Staining 
Midbrain slices were stained so as to highlight tyrosine hydroxylase (TH) within the 
substantia nigra pars compacta (SNc) and nearby ventral tegmental area (VTA). TH is an 
enzyme required for the production of dopamine, thus is more highly concentrated in 
dopaminergic neurons. The images in Figure 5 were taken from midbrain slices from a sham-
operated female and an ovariectomized female. TH is stained bright yellow in the pictures, 
indicating where dopaminergic neurons and their associated processes lie. The right side of the 
brains received an intrastriatal injection of 6-OHDA while the left sides of the brain were left 
unlesioned. As can be observed in Figure 5, the concentration of TH, and thereby dopaminergic 
neurons, is greatly reduced in the lesioned SNc of both the sham-operated and ovariectomized 
females. Some neurodegeneration also appears to have occurred in the VTA simply due to its 
proximity. Comparative quantification of TH concentration in the SNc is pending. 
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Figure 5. Midbrain slices highlighting unilateral lesioning in both groups of female mice. 
 
Pole Test 
Due to anomalous estrous cycling in one ovariectomized female, pole test behavioral data 
were analyzed for only 8 of the 9 females. Each female completed three trials for each testing 
day, and testing was conducted once a week for 5 of the 6 total experiment weeks. The mice 
were analyzed based on their time to turn, time to descend, and quality of descent, and the 
average of the three trials was recorded for each mouse; results were then separated according to 
the type of surgery each mouse received. Figure 6 below shows graphical results from the pole 
test. Blue indicates data from sham-operated females, while red indicates data from 
ovariectomized females; the green arrow indicates the time point at which all the mice received 
unilateral intrastriatal injections of 6-OHDA. Figure 6 graph A illustrates the average time to 
turn for each of the groups of mice over course of the experiment. Figure 6 graph B illustrates 
the average time to descend for each of the groups of mice over the course of the experiment. 
Figure 6 graph C indicates the score of descent for each of the groups of mice over the course of 
the experiment, with 5 indicating the highest possible score. 
While no apparent pattern can be seen for either average time to turn or average score, it 
appears that the average time to descend increased for both groups of females after both types of 
surgery as well as after receiving injections of 6-OHDA. However, statistical analysis showed 
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that no significant difference between sham-operated females or ovariectomized females existed 
either before 6-OHDA or after 6-OHDA for average time to turn, average time to descend, or 
average score. P-values are indicated on each graph in Figure 6. 
 
 
 
Figure 6. Graphical representation of average time to turn (A), average time to descend (B), and 
average score of descent (C) for both sham-operated and ovariectomized mice. 
 
Interestingly, while analyzing video recordings of the pole test, spontaneous rotation was 
observed as the mice descended the pole, particularly after the mice received intrastriatal 
injections of 6-OHDA. This phenomenon has not been previously described in similar studies 
utilizing the pole test and 6-OHDA rodent models, so I went back through all the videos and 
quantified the number of 360° rotations around the pole for each mouse during the time of 
descent. During the weeks prior to 6-OHDA injections, the average number of rotations was 
relatively low, collectively less than one turn as the mice descended. However, the number of 
rotations immediately increased in both groups after receiving 6-OHDA injections; some of the 
mice rotated around the pole as many as 5 times before reaching the base. Figure 7 below 
illustrates the increase in rotations observed in the mice. Blue indicates data from sham-operated 
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females, while red indicates data from ovariectomized females; the green arrow indicates the 
time point at which all the mice received unilateral intrastriatal injections of 6-OHDA. 
In addition to the observable increase in rotations for each group, statistical analysis 
revealed a significant difference in the average number of rotations of sham-operated and 
ovariectomized females, with more rotation occurring in ovariectomized females (p=0.006). P-
values are also displayed in Figure 7. 
 
Figure 7. Graphical representation of average number of rotations for both sham-operated and 
ovariectomized mice.  
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CHAPTER IV 
CONCLUSION 
 
 
Data Implications 
Results from vaginal smearing indicate that ovariectomy interrupts estrous cycling in 
female mice. Estrous cycling is dependent upon sex hormone fluctuation, similar to menstrual 
cycling in humans. By removing the primary source of estrogen in our female mice, we impeded 
their ability to continue cycling. Given this visible change, we were then able to compare sham-
operated mice and ovariectomized mice as having estrogen and lacking estrogen, respectively. 
Intrastriatal injection of 6-OHDA causes retrograde degeneration of dopaminergic 
neurons in the SNc. Midbrain slice staining shows that the lesioned side of the brain has 
qualitatively lower amounts of TH, indicating fewer dopaminergic neurons and less dopamine 
unilaterally. Such a sizeable dopamine imbalance could be responsible for the spontaneous 
rotational behavior observed during the pole test. The task requires the mouse to turn its entire 
body upside down, descend, and dismount the pole; this requires extensive motor regulation, 
which likely induces dopamine release in the SNc. With a neurotoxin-induced dopamine 
imbalance in this brain region, motor function will consequently be imbalanced. Accordingly, a 
substantial dopamine imbalance presents as rotational behavior. 
The significantly increased number of rotations seen in ovariectomized female mice 
supports the belief that estrogen is neuroprotective. The ovariectomized females, who had little 
to no estrogen, showed a greater degree of rotational behavior; this indicates a greater imbalance 
in dopaminergic neurons. Assuming these mice had a typical amount of dopaminergic neurons to 
begin with, the heightened imbalance suggests that they experienced more extensive 
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neurodegeneration when subjected to intrastriatal injections of 6-OHDA than did their estrogen-
intact counterparts. 
 Because rotational behavior usually requires extensive dopamine release, as achieved 
using drugs such as apomorphine or amphetamines, the spontaneous rotations observed during 
the pole test are extraordinary. Results support the viability of the test, indicating that the pole 
test is successful in causing dopamine release in the SNc. Furthermore, the spontaneous 
rotational behavior provides an exciting new alternative to drug-induced behavior testing. This is 
especially advantageous in the realm of drug testing. The pole test not only provides 
measurements for motor capability, but also an assessment of dopamine release without the need 
for additional drugs, sparing the concern about drug-drug interactions that may arise in other 
models. 
Future Directions 
 Having observed a significant increase in rotational behavior in ovariectomized females, 
the next step is to quantify and compare TH concentrations in both ovariectomized and sham-
operated females. If the behavioral imbalance is supported by corresponding TH concentration 
imbalance, then this would further promote the impression that estrogen has a neuroprotective 
role. 
 If this is true, then estrogen may become a valuable component in a neuroprotective drug 
for PD. Future research will likely focus on the benefit of adding estrogen or estrogen derivatives 
to PD drugs undergoing testing, such as cytisine. One drawback to using estrogen as a drug is 
that it naturally causes feminizing effects, or the formation of female secondary sex 
characteristics, which can be undesirable. However, a non-feminizing derivative of estrogen may 
provide a useful addition to a therapeutic drug for PD. 
  
31 
REFERENCES 
 
 
1. Moustafa A, Chakravarthy S, Phillips J, Gupta A, Keri S, Polner B, Frank M, Jahanshahi M. 
Motor symptoms in Parkinson’s disease: A unified framework. Neurosci Biobehav Rev. 
2019;68:727-740. 
 
 
2. Pfeiffer R, Bodis-Wollner I. Parkinson’s disease and nonmotor dysfunction. Edited by 
Ronald F. Pfeiffer and Ivan Bodis-Wollner. Humana Press; 2005.  
 
 
3. Dorsey ER, Sherer T, Okun MS, Bloem BR, Brundin P, Langston JW. The Emerging 
Evidence of the Parkinson Pandemic. J Parkinsons Dis. 2018;8:S3-S8. 
 
 
4. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic 
burden of Parkinson’s disease in the United States. Mov Disord. 2013;28(3):311-318.  
 
 
5. Kaur R, Mehan S, Singh S. Understanding multifactorial architecture of Parkinson’s disease: 
pathophysiology to management. Neurol Sci. 2019;40(1):13-23.  
 
 
6. Hernandez-Baltazar D, Zavala-Flores LM, Villanueva-Olivo A. The 6-hydroxydopamine 
model and parkinsonian pathophysiology: Novel findings in an older model. Neurologia. 
2017;32(8):533-539. 
 
 
7. Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. 
Free Radical Biology and Medicine. 2013;62:132-144.  
 
 
8. Gillies GE, Pienaar IS, Vohra S, Qamhawi Z. Sex differences in Parkinson’s disease. Front 
Neuroendocrinol. 2014;35(3):370-384.  
 
 
9. Elbaz A, Bower JH, Maraganore DM, et al. Risk tables for parkinsonism and Parkinson’s 
disease. Journal of Clinical Epidemiology. 2002;55(1):25-31.  
 
 
10. Mozley L, Gur RC, Mozley P, Gur RE. Striatal dopamine transporters and cognitive 
functioning in healthy men and women. Am J Psychiatry. 2001;158(9):1492-1499. 
 
32 
11. Walton CC, Shine JM, Mowszowski L, Naismith SL, Lewis SJG. Freezing of gait in 
Parkinson’s disease: current treatments and the potential role for cognitive training. Restor 
Neurol Neurosci. 2014;32(3):411-422. 
 
 
12. Vajda FJE. Neuroprotection and neurodegenerative disease. J Clin Neurosci. 2002;9(1):4-8. 
 
 
13. Fagerström K, Pomerleau O, Giordani B, Stelson F. Nicotine may relieve symptoms of 
Parkinson’s disease. Psychopharmacology (Berl). 1994;116(1):117-119.  
 
 
14. Tutka P, Vinnikov D, Courtney RJ, Benowitz N. Cytisine for nicotine addiction treatment: A 
review of pharmacology, therapeutics and an update of clinical trial evidence for smoking 
cessation. Addiction. 2019;14(11):1951-1969. 
 
 
15. Smith AD, Bolam JP. The neural network of the basal ganglia as revealed by the study of 
synaptic connections of identified neurones. Trends Neurosci. 1990;13(7):259-265. 
 
 
16. Brys I, Nunes J, Fuentes R. Motor deficits and beta oscillations are dissociable in an alpha-
synuclein model of Parkinson’s disease. Eur J Neurosci. 2017;46(3):1906-1917.  
 
 
17. Souza V, Mendes E, Casaro M, Antiorio A, Oliveira F. Description of ovariectomy protocol 
in mice. Methods Mol Biol. 2019;1916:303-309. 
 
 
18. Cora M, Kooistra L, Travlos G. Vaginal cytology of the laboratory rat and mouse: review 
and criteria for the staging of the estrous cycle using stained vaginal smears. Toxicol Pathol. 
2015;43(6):776-793. 
 
 
19. McLean A, Valenzuela N, Fai S, Bennett S. Performing vaginal lavage, crystal violet 
staining, and vaginal cytological evaluation for mouse estrous cycle staging identification. J 
Vis Exp. 2012;(67):4389.  
 
 
20. Taylor TN, Greene JG, Miller GW. Behavioral phenotyping of mouse models of Parkinson’s 
disease. Behav Brain Res. 2010;211(1):1-10. 
 
 
21. Boix J, Padel T, Paul G. A partial lesion model of Parkinson’s disease in mice – 
Characterization of a 6-OHDA-induced medial forebrain bundle lesion. Behav Brain Res. 
2015;284:196-206. 
33 
22. Hudson JL, van Horne CG, Strömberg I, et al. Correlation of apomorphine- and 
amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-
hydroxydopamine lesioned rats. Brain Res. 1993;626(1-2):167-174.  
 
 
23. Seibenhener M, Wooten M. Use of the Open Field Maze to Measure Locomotor and 
Anxiety-like Behavior in Mice. J Vis Exp. 2015;(96):e52434.  
 
 
24. Glajch KE, Fleming SM, Surmeier DJ, Osten P. Sensorimotor assessment of the unilateral 6-
hydroxydopamine mouse model of Parkinson’s disease. Behav Brain Res. 2012;230(2):309-
316.  
 
 
25. Dunnett S, Torres E, Annett L. A lateralised grip strength test to evaluate unilateral 
nigrostriatal lesions in rats. Neurosci Lett. 1998;246(1):1-4.  
